1. Home
  2. SKYE vs FRGE Comparison

SKYE vs FRGE Comparison

Compare SKYE & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • FRGE
  • Stock Information
  • Founded
  • SKYE 2012
  • FRGE 2014
  • Country
  • SKYE United States
  • FRGE United States
  • Employees
  • SKYE N/A
  • FRGE N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • FRGE Computer Software: Prepackaged Software
  • Sector
  • SKYE Health Care
  • FRGE Technology
  • Exchange
  • SKYE Nasdaq
  • FRGE Nasdaq
  • Market Cap
  • SKYE 176.8M
  • FRGE 302.3M
  • IPO Year
  • SKYE N/A
  • FRGE N/A
  • Fundamental
  • Price
  • SKYE $6.06
  • FRGE $1.53
  • Analyst Decision
  • SKYE Strong Buy
  • FRGE Buy
  • Analyst Count
  • SKYE 4
  • FRGE 2
  • Target Price
  • SKYE $19.25
  • FRGE $5.25
  • AVG Volume (30 Days)
  • SKYE 324.8K
  • FRGE 378.9K
  • Earning Date
  • SKYE 01-01-0001
  • FRGE 08-06-2024
  • Dividend Yield
  • SKYE N/A
  • FRGE N/A
  • EPS Growth
  • SKYE N/A
  • FRGE N/A
  • EPS
  • SKYE N/A
  • FRGE N/A
  • Revenue
  • SKYE N/A
  • FRGE $73,584,000.00
  • Revenue This Year
  • SKYE N/A
  • FRGE $27.87
  • Revenue Next Year
  • SKYE N/A
  • FRGE $36.74
  • P/E Ratio
  • SKYE N/A
  • FRGE N/A
  • Revenue Growth
  • SKYE N/A
  • FRGE 13.49
  • 52 Week Low
  • SKYE $1.44
  • FRGE $1.31
  • 52 Week High
  • SKYE $19.41
  • FRGE $4.02
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 36.48
  • FRGE 52.20
  • Support Level
  • SKYE $5.77
  • FRGE $1.36
  • Resistance Level
  • SKYE $6.83
  • FRGE $1.63
  • Average True Range (ATR)
  • SKYE 0.73
  • FRGE 0.08
  • MACD
  • SKYE 0.12
  • FRGE 0.02
  • Stochastic Oscillator
  • SKYE 34.47
  • FRGE 61.11

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About FRGE Forge Global Holdings Inc.

Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The Company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.

Share on Social Networks: